§ 002 · Section 2 · The destination question

Why Mexico, and not Panama or Cayman?

A country-by-country look at the global stem-cell landscape. Mexico, Panama, Cayman, Costa Rica, Germany, Japan, Thailand. Why we landed where we did, and what an American patient is actually choosing between.

Section length 7 articles · ≈ 51 min
Audience Patient · spouse · MD
Reading order 2.1 → 2.7 · or any one

Prefer to watch?

Mexico versus everywhere else.

Short on time? The video makes the country-by-country case in one pass: why Mexico, and why not Panama, Cayman, Germany, or Japan. Keep scrolling for the full version.

Rather read? The full breakdown continues below
Section at a glance
The question Six countries have credible
regenerative-medicine industries.
One of them is a 25-minute
drive from San Diego.
II
The answer Mexico, specifically Tijuana,
specifically because geography
compounds with regulation
in a way nothing else does.

Read in order, this section moves from Mexico for Americans → Mexico vs. Panama & Cayman → Mexico vs. Germany & Japan → Tijuana, specifically → safety → the global map → sources. Each article holds up alone if you only have time for one.

· The argument, in 600 words

The case is not that Mexico is the best. The case is that geography compounds.

If the question were only regulation, Germany would win: older industry, deeper paper trail, and a payment-for-performance framework that has been in continuous operation since 2002. If the question were only cost, Thailand or India would win. If it were only privacy, Cayman would win. The reason Mexico keeps coming out on top in our internal comparisons, and the reason we built Celva there, is that none of those questions exists in isolation for an American patient.

The first month after a cell-therapy infusion is the highest-yield window for the protocol: physical therapy schedules, hyperbaric oxygen sessions, follow-up labs, hyperbaric or PRP supplements, and the occasional repeat infusion. Patients who fly home and never return for follow-up tend to get less from the protocol than those who come back for that window. Distance matters because compliance matters.

Tijuana solves the distance problem in a way no other destination does. From downtown San Diego or San Diego International, our Escalade reaches Hospital Angeles in about 25 to 30 minutes, door to door: roughly 20 minutes to the border and 5 to 10 minutes across. A patient can land at SAN in the morning, ride in with a team member, be in the hospital by mid-morning, and be home by dinner the same day. The follow-up loop is a series of long weekends rather than a series of international trips. (The Cross Border Xpress pedestrian bridge connecting SAN to Tijuana airport exists; it's an option for patients who insist on flying themselves into TIJ, but our concierge transport doesn't use it.) That is the geographic half.

The regulatory half is the COFEPRIS framework. Like most of Europe and Asia, Mexico regulates the physician as the responsible actor, not the manufacturer. That places allogeneic umbilical-cord MSC preparations, which are the strongest evidence base in regenerative medicine right now, inside the legal corridor when administered by a properly-licensed clinic. It is the same framework that lets Germany run its therapy industry; it happens to sit next door.

This section is not an argument that Mexico is the unique answer. There are seven articles, and one of them is dedicated entirely to where Mexico is worse than the alternatives Germany has deeper records, Japan has deeper science, Panama has a friendlier customs regime for cryopreserved imports. The argument is narrower: when you compound geography, regulation, hospital infrastructure, language, and cost, Mexico is the one that wins on all five at once.

§ A · The three things that compound

Three variables. One country wins all three.

The destination question is rarely about a single dimension. Cell therapy compounds distance, regulation, and infrastructure in a way the brochures don't surface. Below, the three variables, and why they snap together in one place.

i.
Variable one

Geography.

San Diego International to Hospital Angeles, door to door: ≈3 hours. Most patients fly home the day of the second infusion. Panama is six flight hours and a customs declaration; Cayman is connecting flights from most U.S. cities.

MedianSAN ↔ TIJ · CBX
ii.
Variable two

Regulation.

COFEPRIS regulates the practitioner the same posture Germany, Japan, and most of Europe take. Allogeneic preparations are inside the corridor, provided the physician is properly licensed and the facility is registered. Panama and Cayman use a lighter framework that is more permissive but produces a less complete paper trail.

FrameworkCOFEPRIS · 2017
iii.
Variable three

Hospital density.

Tijuana has nine major private hospitals inside a 15 km radius, the highest hospital density per capita in Latin America. Cell therapy is a procedure, but it sometimes becomes a hospital. Having one across the street matters.

national hospital certification9 · Tijuana metro

The compounding, not the singular. Each variable taken alone has a winner that is not Mexico. Panama edges on customs simplicity. Germany edges on records. Japan edges on basic science. When you stack the three variables that actually predict outcomes for an American patient: distance, framework, hospital backstop, they compound at the intersection, and the intersection happens to be in Tijuana.

§ B · The shape of the choice

Four numbers that explain where Americans go.

1.4M
U.S. residents per year who cross
into Mexico for medical or dental care. U.S. State Dept · medical-travel travel-advisory data · 2024
9
Major private hospitals inside a
15 km radius of central Tijuana. Angeles Health, ABC, and Hospitales MAC corporate disclosures · Jan 2026
25min
San Diego airport or downtown to Hospital Angeles,
in our Escalade. Door to door. Median patient transfer · last 12 months · Celva operations
68%
Of cross-border cell-therapy patients
who return for at least one follow-up infusion. Celva clinical follow-up records
The seven articles, in order

Seven articles. About fifty-one minutes of reading.

Each one was edited to be readable on its own. Read in order, they construct a comparison; read individually, they answer a specific question. The last one is a footnote page, every numerical claim in the section, sourced.

  1. I
    § 2.1 · The American vantage

    Why Mexico, for Americans.

    The case for Mexico from an American patient's vantage. Proximity, regulation, cost, follow-up, and the practical realities of cross-border care.

    8 minPatient · MD
    Read →
  2. II
    § 2.2 · The Latin-American shortlist

    Mexico vs. Panama and Cayman.

    A side-by-side on the three Latin-American destinations Americans most often consider. Regulatory framework, hospital infrastructure, cost, distance.

    9 minPatient · MD
    Read →
  3. III
    § 2.3 · The premium destinations

    Mexico vs. Germany and Japan.

    How Mexico compares to the established European and Asian destinations. What you get for the higher cost, and what you don't.

    7 minPatient · MD
    Read →
  4. IV
    § 2.4 · The city, not the country

    Tijuana, not Cancún.

    The reason almost every cross-border MSC program for Americans is in Tijuana, not the resort cities further south. Hospital density, U.S. proximity, ground transit.

    6 minPatient
    Read →
  5. V
    § 2.5 · The safety record

    Medical-tourism safety, by the numbers.

    What the actual safety record of U.S. → Mexico medical travel looks like. Infection rates, complication rates, the international hospital standard, and how it compares to the U.S. baseline.

    9 minPatient · MD
    Read →
  6. VI
    § 2.6 · The full atlas

    The global map, in one page.

    Every country with a credible regenerative medicine industry, on one page, with the regulatory framing each one operates under.

    8 minMD
    Read →
  7. VII
    § 2.7 · The footnotes

    Mexico: sources & claims.

    A footnote page. Every claim made in Section 2, with its source, in one place. If you only trust documents, start here.

    4 min · referenceMD
    Read →
  1. i. Will not

    A claim that Mexico is safer than the U.S.

    It is not. It is comparably safe inside internationally accredited facilities for the procedures we run. The article on safety is the one that spells out the actual numbers.

  2. ii. Will not

    An argument that Panama and Cayman are scams.

    They are not. There are good clinics in both. They sit inside a lighter framework that we judged, on balance, less defensible for an American patient population with our protocols. Reasonable people disagree.

  3. iii. Will not

    A reason to skip Germany or Japan.

    For some indications and some patients, they are the right answer and we will say so. The comparison article spells out which indications and which patients, and includes the indications where we'd refer out.

  4. iv. Will not

    A travelogue. "You'll love Tijuana."

    Maybe you will. That is not the relevant question. The relevant question is whether Tijuana solves a logistical problem that other destinations do not. The article on the city, not the country, walks through that.

  5. v. Will not

    A claim that our practice is the only good one.

    It isn't. We can name three Tijuana clinics we'd send a family member to, and one we'd send to over us for a specific indication. That conversation belongs on a consult call, not a section landing page.

§ D · Begin the section

Start with the American vantage. It frames the rest.

If you are going to read one article in this section, read this one. Most of the questions we get on consult calls trace back to the proximity-plus-regulation argument it makes in the first 800 words.

Read § 2.1 · Why Mexico, for Americans → Back to all sections